ReviewExpert opinion on biological therapy2016
Recent advances and future of immunotherapy for glioblastoma.
Review in Expert opinion on biological therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme.Human vaccines & immunotherapeutics · 2017Pooled it
- Engendered nanoparticles for treatment of brain tumors.Oncology research · 2025Review
- Pentraxin 3: A Main Driver of Inflammation and Immune System Dysfunction in the Tumor Microenvironment of Glioblastoma.Cancers · 2024Review
- Review
- Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies.Advanced drug delivery reviews · 2021Review
- Review
- Article
- A narrative review of research progress on drug therapies for glioblastoma multiforme.Annals of translational medicine · 2021Review
- Viral Gene Therapy for Glioblastoma Multiforme: A Promising Hope for the Current Dilemma.Frontiers in oncology · 2021Review
- Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma.Frontiers in oncology · 2021Review
- Long Noncoding RNA NONHSAT079852.2 Contributes to GBM Recurrence by Functioning as a ceRNA for has-mir-10401-3p to Facilitate HSPA1A Upregulation.Frontiers in oncology · 2021Article
- Current Approaches for Glioma Gene Therapy and Virotherapy.Frontiers in molecular neuroscience · 2021Review
- Nanomedicine-based immunotherapy for central nervous system disorders.Acta pharmacologica Sinica · 2020Review
- Potential roads for reaching the summit: an overview on target therapies for high-grade gliomas.Acta bio-medica : Atenei Parmensis · 2020Review
- Expression profile of ACTL8, CTCFL, OIP5 and XAGE3 in glioma and their prognostic significance: a retrospective clinical study.American journal of translational research · 2020Article
- Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis.Frontiers in immunology · 2020Review
- High Dimensional Mass Cytometry Analysis Reveals Characteristics of the Immunosuppressive Microenvironment in Diffuse Astrocytomas.Frontiers in oncology · 2020Article
- Review
- Changing paradigms for targeted therapies against diffuse infiltrative gliomas: tackling a moving target.Expert review of neurotherapeutics · 2019Review
- Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.Molecular & cellular proteomics : MCP · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionOutcome for glioma (GBM) remains dismal despite advances in therapeutic interventions including chemotherapy, radiotherapy and surgical resection. The overall survival benefit observed with immunotherapies in cancers such as melanoma and prostate cancer has fuelled research into evaluating immunotherapies for GBM. AREAS COVERED: Preclinical studies have brought a wealth of information for improving the prognosis of GBM and multiple clinical studies are evaluating a wide array of immunotherapies for GBM patients. This review highlights advances in the development of immunotherapeutic approaches. We discuss the strategies and outcomes of active and passive immunotherapies for GBM including vaccination strategies, gene therapy, check point blockade and adoptive T cell therapies. We also focus on immunoediting and tumor neoantigens that can impact the efficacy of immunotherapies. EXPERT OPINION: Encouraging results have been observed with immunotherapeutic strategies; some clinical trials are reaching phase III. Significant progress has been made in unraveling the molecular and genetic heterogeneity of GBM and its implications to disease prognosis. There is now consensus related to the critical need to incorporate tumor heterogeneity into the design of therapeutic approaches. Recent data also indicates that an efficacious treatment strategy will need to be combinatorial and personalized to the tumor genetic signature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.